

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Verzenio (abemaciclib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Verzenio (abemaciclib)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Verzenio (abemaciclib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer;

AND

- II. Individual is using as monotherapy for progression following endocrine therapy and prior chemotherapy in the metastatic setting; **OR**
- III. Individual is using in combination with an aromatase inhibitor for initial endocrine therapy; **OR**
- IV. Individual is using fulvestrant as initial endocrine therapy (NCCN 1); **OR**
- V. Individual is using in combination with fulvestrant for progression following endocrine therapy.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: April 15, 2020.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on April 15, 2020.
 - a. Breast Cancer. V3.2020. Revised March 6, 2020.
 - b. Soft Tissue Sarcoma. V6.2019. Revised February 10, 2020.

CRX-ALL-0567-20

PAGE 1 of 2 07/16/2020
New Program Date 11/18/2017

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.